We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients...
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.05 | 4 | 1.25 | 1.42 | 1.25 | 225896 | 1.32041459 | CS |
| 4 | -0.12 | -8.45070422535 | 1.42 | 1.46 | 1.22 | 234337 | 1.32065224 | CS |
| 12 | -0.05 | -3.7037037037 | 1.35 | 1.65 | 1.22 | 408389 | 1.43074258 | CS |
| 26 | -2.8 | -68.2926829268 | 4.1 | 4.625 | 1.02 | 323739 | 1.51630302 | CS |
| 52 | -3.57 | -73.3059548255 | 4.87 | 7.64 | 1.02 | 214034 | 2.49967087 | CS |
| 156 | -19.73 | -93.8183547313 | 21.03 | 26.4899 | 1.02 | 160396 | 5.81703624 | CS |
| 260 | -21.1 | -94.1964285714 | 22.4 | 37.61 | 1.02 | 166169 | 6.75614237 | CS |
Monksdream
1 month ago
Monksdream
2 months ago
herbied47
6 months ago
herbied47
6 months ago
Tacostocks
6 months ago
Money hunt
6 months ago
Tacostocks
6 months ago
AJ Freely
9 months ago
Tartiaboy
1 year ago
TrendTrade2016
2 years ago
TrendTrade2016
2 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
